Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017

  • ID: 4311881
  • Report
  • 30 pages
  • Global Markets Direct
1 of 5
Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017'; Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Human Papillomavirus Minor Capsid Protein L2 (L2) - L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dynein in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins.

The report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017' outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Cervical Cancer, Human Papillomavirus (HPV) Associated Cancer, Human Papillomavirus Infections, Genital Warts (Condylomata Acuminata) and Warts.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)
  • The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Human Papillomavirus Minor Capsid Protein L2 (L2) - Overview
  3. Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Human Papillomavirus Minor Capsid Protein L2 (L2) - Therapeutics Assessment
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Human Papillomavirus Minor Capsid Protein L2 (L2) - Companies Involved in Therapeutics Development
  13. Agilvax Inc
  14. Cancer Research Technology Ltd
  15. Pathovax LLC
  16. Human Papillomavirus Minor Capsid Protein L2 (L2) - Drug Profiles
  17. AX-03 - Drug Profile
  18. Product Description
  19. Mechanism Of Action
  20. R&D Progress
  21. PVX-01 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. RGVax - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. TA-CIN - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Human Papillomavirus Minor Capsid Protein L2 (L2) - Dormant Products
  38. Human Papillomavirus Minor Capsid Protein L2 (L2) - Product Development Milestones
  39. Featured News & Press Releases
  40. Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest
  41. Sep 06, 2016: Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate
  42. Feb 03, 2015: Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus
  43. Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine
  44. Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight
  45. Appendix
  46. Methodology
  47. Coverage
  48. Secondary Research
  49. Primary Research
  50. Expert Panel Validation
  51. Contact Us
  52. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Pipeline by Agilvax Inc, H1
  11. Pipeline by Cancer Research Technology Ltd, H1
  12. Pipeline by Pathovax LLC, H1
  13. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Therapy Areas, H1
  2. Number of Products under Development by Indications, H1
  3. Number of Products by Molecule Types, H1
  4. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Agilvax Inc
  • Cancer Research Technology Ltd
  • Pathovax LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll